RSV Vaccine and Treatment Shortages: What Parents Must Know to Protect Infants

There is a shortage of the RSV vaccine for infants due to supply issues, with limited availability of the long-acting monoclonal antibody immunization Beyfortus (nirsevimab). The shortage primarily affects 100 mg-dose prefilled syringes used for infants weighing less than 11 pounds. The CDC recommends prioritizing available doses for infants at the highest risk of severe infection and suspending the use of nirsevimab in children aged 8 months to 19 months who are eligible for an alternative immunization. Prenatal care physicians should inform pregnant patients about the supply concerns. Families are advised to practice everyday preventive measures to limit the spread of RSV, such as handwashing and staying home when symptoms occur. RSV infection during infancy can increase the child's risk for asthma development. Multiple vaccine options are available for adults to protect against RSV.